Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
GlaxoSmithKline ( (GB:GSK) ) has shared an announcement.
GSK has disclosed the vesting of awards under its 2017 Performance Share Plan for senior executives, following a three-year performance period from 2023 to 2025. The plan, which links long-term incentives to metrics such as total shareholder return, sales, profit, pipeline progress and environmental goals, vested at 82% of maximum, with 18% of the awards lapsing.
The company reported that sales of £99.03bn and profit of £30.22bn both exceeded the thresholds required for full vesting on those measures, while all criteria tied to its Nature Net Positive and Climate Net Zero 2030 targets were met or surpassed. Chief executive Luke Miels, Europe president Lynn Baxter and chief people officer Diana Conrad received vested ordinary shares, and each sold a portion on the London Stock Exchange to cover tax liabilities at a share price of about £21.60, underscoring the alignment of executive pay with recent financial and ESG performance.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £20.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Neutral.
The score is driven primarily by strong profitability and improving recent fundamentals, supported by constructive 2026 guidance and pipeline momentum. Valuation is reasonable with a modest yield, while the main constraint is technical overbought risk and ongoing balance-sheet/earnings-consistency considerations.
To see Spark’s full report on GB:GSK stock, click here.
More about GlaxoSmithKline
GSK plc is a global biopharmaceutical company focused on developing and commercialising prescription medicines and vaccines across multiple therapeutic areas. The group targets large international markets with a portfolio spanning marketed pharmaceutical products and an advancing R&D pipeline, positioning it among the major global pharmaceutical players.
Average Trading Volume: 8,707,514
Technical Sentiment Signal: Buy
Current Market Cap: £87.35B
For an in-depth examination of GSK stock, go to TipRanks’ Overview page.